D. Boral Capital Maintains Buy on NeuroSense Therapeutics, Maintains $14 Price Target

Benzinga · 11/24/2025 15:46
D. Boral Capital analyst Jason Kolbert maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy and maintains $14 price target.